Published in J Clin Psychopharmacol on June 01, 2005
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res (2010) 3.26
A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry (2009) 1.24
Management of antipsychotic-related weight gain. Expert Rev Neurother (2010) 1.07
Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One (2014) 1.02
Salience network and olanzapine in schizophrenia: implications for treatment in anorexia nervosa. Can J Psychiatry (2015) 0.99
Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl) (2007) 0.96
The orexins/hypocretins and schizophrenia. Schizophr Bull (2007) 0.93
Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry (2008) 0.87
Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry (2009) 0.86
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. BMC Psychiatry (2009) 0.85
Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacol Bull (2011) 0.82
The potential role of appetite in predicting weight changes during treatment with olanzapine. BMC Psychiatry (2010) 0.82
Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. Transl Psychiatry (2012) 0.82
Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications. Pharmacogenomics (2011) 0.79
Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder. Ther Clin Risk Manag (2008) 0.79
Pharmacovigilance on olanzapine. Indian J Pharmacol (2010) 0.77
STEPWISE - STructured lifestyle Education for People WIth SchizophrEnia: a study protocol for a randomised controlled trial. Trials (2016) 0.75
Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up. Ther Adv Psychopharmacol (2014) 0.75
Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden. Proc Natl Acad Sci U S A (2007) 0.75
Association Between Weight Gain and Remission Status at 3 Months in First-Episode Schizophrenia. J Clin Psychopharmacol (2016) 0.75
Inadequate coordination of maternal and infant HIV services detrimentally affects early infant diagnosis outcomes in Lilongwe, Malawi. J Acquir Immune Defic Syndr (2011) 2.38
A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol (2011) 2.31
The Tingathe programme: a pilot intervention using community health workers to create a continuum of care in the prevention of mother to child transmission of HIV (PMTCT) cascade of services in Malawi. J Int AIDS Soc (2012) 1.92
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology (2010) 1.47
Implementation and operational research: the impact of option B+ on the antenatal PMTCT cascade in Lilongwe, Malawi. J Acquir Immune Defic Syndr (2015) 1.47
The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. Clin Trials (2004) 1.45
Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res (2008) 1.45
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry (2007) 1.40
Mortality and clinical outcomes in HIV-infected children on antiretroviral therapy in Malawi, Lesotho, and Swaziland. Pediatrics (2012) 1.24
Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord (2002) 1.11
Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry (2006) 1.10
The role of fibroblast growth factor-23 in left atrial volume. Am Heart J (2013) 1.07
Metabolic acidosis may increase fibroblast growth factor-23 and cardiovascular mortality in the community. Kidney Int (2013) 1.07
Vitamin D deficiency and cardiovascular disease. Swiss Med Wkly (2013) 1.06
Short QT syndrome (JANUARY 2013). Cleve Clin J Med (2013) 1.05
Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int J Neuropsychopharmacol (2003) 1.03
Prompt initiation of ART With therapeutic food is associated with improved outcomes in HIV-infected Malawian children with malnutrition. J Acquir Immune Defic Syndr (2012) 1.02
Beyond prevention of mother-to-child transmission: keeping HIV-exposed and HIV-positive children healthy and alive. AIDS (2013) 1.02
Low rates of mother-to-child HIV transmission in a routine programmatic setting in Lilongwe, Malawi. PLoS One (2013) 1.00
Expression of c-fos gene activation during rough and tumble play in juvenile rats. Brain Res Bull (2002) 0.98
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry (2013) 0.98
Linkage, initiation and retention of children in the antiretroviral therapy cascade: an overview. AIDS (2013) 0.95
Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach. Psychiatry Res (2009) 0.91
Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol (2006) 0.90
A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res (2007) 0.89
Alpha-glucosidase inhibitory constituents from Cuscuta reflexa. Chem Pharm Bull (Tokyo) (2002) 0.89
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res (2010) 0.89
Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison. Schizophr Res Treatment (2014) 0.88
Is complement factor H a susceptibility factor for IgA nephropathy? Mol Immunol (2009) 0.87
Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience Scale. Int Clin Psychopharmacol (2008) 0.87
Single or double bubble: sign of trouble! Congenital pyloric atresia: report of two cases and review of literature. J Paediatr Child Health (2007) 0.86
Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithium. J Psychiatr Res (2005) 0.86
Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry (2004) 0.85
Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods. Schizophr Res (2009) 0.85
Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophr Res (2011) 0.84
Brief Report: Impact of Option B+ on the Infant PMTCT Cascade in Lilongwe, Malawi. J Acquir Immune Defic Syndr (2015) 0.84
Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia. Schizophr Res (2010) 0.84
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. J Clin Psychopharmacol (2008) 0.84
Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry (2009) 0.83
Wellens' syndrome and clinical significance of T-wave inversion in anterior precordial leads. Am J Emerg Med (2012) 0.83
Delivering pediatric HIV care in resource-limited settings: cost considerations in an expanded response. AIDS (2013) 0.82
Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry (2011) 0.82
The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial. BMC Psychiatry (2011) 0.81
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. J Clin Psychiatry (2003) 0.81
Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder. BMC Psychiatry (2010) 0.80
Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. Am J Emerg Med (2004) 0.80
HIV-exposed infants: rethinking care for a lifelong condition. AIDS (2013) 0.80
Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder. Ther Clin Risk Manag (2008) 0.79
Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy. Clinicoecon Outcomes Res (2011) 0.79
Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. J Clin Psychiatry (2006) 0.79
Pattern of coronary artery disease with no risk factors under age 35 years. J Ayub Med Coll Abbottabad (2012) 0.78
Enzyme inhibitory constituents from Duranta repens. Chem Pharm Bull (Tokyo) (2002) 0.78
Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials. J Clin Psychopharmacol (2010) 0.78
Pantoprazole-induced acute interstitial nephritis. J Nephrol (2004) 0.77
Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol. J Clin Psychopharmacol (2012) 0.77
Non-hodgkin lymphoma mimicking polymyalgia rheumatica in a young patient. Oman Med J (2008) 0.77
Rapid iron loading in heart and liver in a patient with transfusion dependent thalassaemia after brief poor compliance with iron chelation therapy. Sultan Qaboos Univ Med J (2010) 0.76
HER-2 Positive Breast Cancer - a Mini-Review. Asian Pac J Cancer Prev (2016) 0.76
A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia. Clin Ther (2005) 0.76
Noninvasive therapy for the management of patients with advanced coronary artery disease. Coron Artery Dis (2012) 0.76
Comparing onset of antidepressant action using a repeated measures approach and a traditional assessment schedule. Stat Med (2006) 0.76
The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients. J Am Med Dir Assoc (2003) 0.76
Syncope in Brugada syndrome type 3: an electrocardiographic lesson. Am J Emerg Med (2013) 0.75
A case of childhood vasculitis presenting in adulthood. Am J Emerg Med (2012) 0.75
Therapeutic hypothermia and effects on coagulopathy. Am J Emerg Med (2012) 0.75
Electrocardiographic changes in tricyclic antidepressant toxicity. Am J Emerg Med (2013) 0.75
Testosterone and QT interval. South Med J (2013) 0.75
Incidence and outcome of severe hyponatremia in children and young adults: a single institution experience. Sultan Qaboos Univ Med J (2006) 0.75
Comments on "Optimizing early prediction for antipsychotic response in schizophrenia" by Chang et al. J Clin Psychopharmacol (2009) 0.75
Lead perforation: an uncommon cause of chest pain in a patient with pacemaker. Int J Cardiol (2013) 0.75
Bilateral cuffed tunnelled femoral dialysis catheters. Int J Nephrol Renovasc Dis (2011) 0.75
Ethyl cellulose-based solid matrix system for sustaining release of naproxen. Pak J Biol Sci (2007) 0.75
Digital ischaemia in a renal transplant patient. Nephrol Dial Transplant (2004) 0.75
The tick that stopped the ticker. Int J Cardiol (2013) 0.75
The amazing cardiac amyloidosis: EKG and echocardiogram. Int J Cardiol (2013) 0.75
Urinary bladder auto augmentation using INTEGRA and SURGISIS: an experimental model. Pediatr Surg Int (2009) 0.75
Synthesis of novel quinoxalinone derivatives by conventional and microwave methods and assessing their biological activity. Arch Pharm Res (2011) 0.75
Breast cancer pattern and chemotherapy response--an institutional study in Pakistan. Asian Pac J Cancer Prev (2010) 0.75